Glutamate is now recognized as both a major excitatory transmitter and a potent neurotoxin. In this respect, the regulation of its concentration is a central issue in the physiology and pathology of the CNS. High affinity transport is believed to be responsible for signal termination, the recycling of the transmitter, and the maintenance of glutamate levels in the extracellular space at concentrations below those that might induce excitotoxic injury. These activities underscore the protective capacity of the uptake systems. Paradoxically, recent evidence suggests they may also contribute to the excitotoxic process as a site of glutamate efflux under pathological conditions. The goal of this proposal is a detailed biochemical characterization of these excitatory amino acid transport systems. These experiments are aimed to elucidate the pharmacological and kinetic properties that distinguish each of the individual processes. Particular emphasis is placed on the sodium-dependent glutamate transporter. Recent research has led to the discovery of selective and conformationally restricted inhibitors that now allow an in-depth investigation of this system's heterogeneity, specificity, and mechanism of translocation. Experiments will also be performed in synaptosomes and cultured astrocytes to elucidate the potential for cell specific differences. Current evidence also indicates the existence of several other excitatory amino acid transporters that are distinct from the sodium-dependent system. Investigations will be directed toward the definition of the kinetic and pharmacological properties that are specific to each. To further define the distinctive properties of the transport systems structure/function experiments will also include molecular modeling and the synthesis of a second generation of analogues. The end result of these chemical and biochemical studies will be a series of very well defined transport inhibitors and substrates that will then be used to modulate uptake in vitro and in vivo. Preliminary data in vivo suggests that the inhibition of transport can modify the susceptibility of neurons to glutamate- mediated injury. Experiments will build on these results to define the role of transport in maintaining a viable extracellular environment and protecting neurons from excitotoxic injury. Overall, these experiments should provide significant insight into the properties of the excitatory amino acid transport systems and the role they may play in regulating the physiological and/or pathological levels of glutamate in the CNS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS030570-03
Application #
2268527
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Project Start
1992-12-01
Project End
1996-11-30
Budget Start
1994-12-01
Budget End
1995-11-30
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Montana
Department
Other Health Professions
Type
Schools of Pharmacy
DUNS #
City
Missoula
State
MT
Country
United States
Zip Code
59812
Ahmed, S Kaleem; Etoga, Jean-Louis G; Patel, Sarjubhai A et al. (2011) Use of the hydantoin isostere to produce inhibitors showing selectivity toward the vesicular glutamate transporter versus the obligate exchange transporter system x(c)(-). Bioorg Med Chem Lett 21:4358-62
Etoga, Jean-Louis G; Ahmed, S Kaleem; Patel, Sarjubhai et al. (2010) Conformationally-restricted amino acid analogues bearing a distal sulfonic acid show selective inhibition of system x(c)(-) over the vesicular glutamate transporter. Bioorg Med Chem Lett 20:2680-3
Patel, Sarjubhai A; Rajale, Trideep; O'Brien, Erin et al. (2010) Isoxazole analogues bind the system xc- transporter: structure-activity relationship and pharmacophore model. Bioorg Med Chem 18:202-13
Ye, Ran; Rhoderick, Joseph F; Thompson, Charles M et al. (2010) Functional expression, purification and high sequence coverage mass spectrometric characterization of human excitatory amino acid transporter EAAT2. Protein Expr Purif 74:49-59
Mavencamp, Terri L; Rhoderick, Joseph F; Bridges, Richard J et al. (2008) Synthesis and preliminary pharmacological evaluation of novel derivatives of L-beta-threo-benzylaspartate as inhibitors of the neuronal glutamate transporter EAAT3. Bioorg Med Chem 16:7740-8
Queen, Susan A; Kesslak, J Patrick; Bridges, Richard J (2007) Regional distribution of sodium-dependent excitatory amino acid transporters in rat spinal cord. J Spinal Cord Med 30:263-71
Bridges, Richard J; Esslinger, C Sean (2005) The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacol Ther 107:271-85
Esslinger, C Sean; Agarwal, Shailesh; Gerdes, John et al. (2005) The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3. Neuropharmacology 49:850-61
Patel, Sarjubhai A; Warren, Brady A; Rhoderick, Joseph F et al. (2004) Differentiation of substrate and non-substrate inhibitors of transport system xc(-): an obligate exchanger of L-glutamate and L-cystine. Neuropharmacology 46:273-84
Warren, Brady A; Patel, Sarjubhai A; Nunn, Peter B et al. (2004) The Lathyrus excitotoxin beta-N-oxalyl-L-alpha,beta-diaminopropionic acid is a substrate of the L-cystine/L-glutamate exchanger system xc-. Toxicol Appl Pharmacol 200:83-92

Showing the most recent 10 out of 24 publications